Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772989 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT04772989 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 94 participants.
The verdict
NCT04772989, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
Interventions
- DRUG Zimberelimab
- DRUG AB308
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2025-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04772989
The ClinicalTrials.gov registry entry for NCT04772989 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zimberelimab is the first listed.
NCT04772989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04772989 about?
NCT04772989 is a clinical study titled "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies". This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
What is the current status of trial NCT04772989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2021-03-19. Estimated completion is 2025-08-25.
What interventions are being tested in trial NCT04772989?
The interventions under investigation include: Zimberelimab (DRUG), AB308 (DRUG).
Who is sponsoring clinical trial NCT04772989?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.